Merck has strong fourth quarter as COVID-19 treatment debuts
The blockbuster cancer treatment Keytruda pushed Merck past fourth-quarter expectations, and the drugmaker’s COVID-19 treatment debuted with nearly $1 billion in sales By TOM MURPHY AP Health Writer February 3, … Read More
![]()

